Modulated release of 5-fluorouracil from pH-sensitive and colon targeted pellets: An industrially feasible approach

Drug Development and Industrial Pharmacy

Volumn 39, Issue 1, 2013, Pages 138-145

  Kulthe, S S ^a   Bahekar, J K ^a   Godhani, C C ^a   Choudhari, Y M ^a   Inamdar, N N ^a   Mourya, V K ^a  

^a GOVERNMENT COLLEGE OF PHARMACY   (India)

Author keywords

5 fluorouracil; Colon targeting; Fluidized bed processor; Optimization; Pellets

Indexed keywords

EUDRAGIT; FLUOROURACIL; HYDROXYPROPYLMETHYLCELLULOSE;

ARTICLE; CONTROLLED DRUG RELEASE; DRUG COATING; DRUG INDUSTRY; DRUG PELLET; FLOW KINETICS; IN VITRO STUDY; PARTICLE SIZE; PH; SCANNING ELECTRON MICROSCOPY; SPHERONIZATION;

ANTIMETABOLITES, ANTINEOPLASTIC; COLON; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG STABILITY; FLUOROURACIL; HYDROGEN-ION CONCENTRATION; INTESTINAL ABSORPTION; MICROSCOPY, ELECTRON, SCANNING; SOLUBILITY;

EID: 84871223727     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.660951     Document Type: Article

References (35)

1. Jain A, Gupta Y, Jain SK. (2007). Perspectives of biodegradable natural polysaccharides for site-Specific drug delivery to the colon. J Pharm Pharm Sci, 10:86-128. (Pubitemid 46692379)
2. http://globocan.iarc.fr/factsheets/cancers/colorectal.asp (Accessed on 19 Jan. 2012
3. Spears CP, Shahinian AH, Moran RG, Heidelberger C, Corbett TH. (1982). In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-Sensitive and -resistant murine colon adenocarcinomas. Cancer Res, 42:450-456. (Pubitemid 12173578)
4. Wei H, Qing D, De-Ying C, Bai X, Li-Fang F. (2008). Study on colonspecific pectin/ethylcellulose film-Coated 5-fluorouracil pellets in rats. Int J Pharm, 348:35-45.
5. Shishu, Gupta N, Aggarwal N. (2007). Stomach-Specific drug delivery of 5-Fluorouracil using floating alginate beads. AAPS Pharm Sci Tech, 8:E143-E149.
6. Goto T, Tomizawa N, Kobayashi E, Fujimura A. (2004). A comparative pharmacology study between the intracolonic and oral routes of 5-FU administration in a colon cancer-bearing Yoshida sarcoma rat model. J Pharmacol Sci, 95:163-173. (Pubitemid 38899685)
7. Chirstophidis N, Vajda FJ, Lucas I, Drummer O, Moon WJ, Louis WJ. (1978). Fluorouracil therapy in patients with carcinoma of the large bowel: A pharmacokinetic comparison of various rates and routes of administration. Clin Pharmacokinet, 3:330-336. (Pubitemid 8375210)
8. Basit AW. (2005). Advances in colonic drug delivery. Drugs, 65:1991-2007. (Pubitemid 41324059)
9. Asghar LF, Chandran S. (2006). Multiparticulate formulation approach to colon specific drug delivery: Current perspectives. J Pharm Pharm Sci, 9:327-338. (Pubitemid 46614339)
10. Lai H, Zhu F, Yuan W, He N, Zhang Z, Zhang X et al. (2011). Development of multiple-unit colon-Targeted drug delivery system by using alginate: In vitro and in vivo evaluation. Drug Dev Ind Pharm, 37:1347-1356.
11. Watts PJ, Lllum L. (1997). Colonic drug delivery. Drug Dev Ind Pharm, 23:893-913. (Pubitemid 27406363)
12. Sinha VR, Kumria R. (2004). Polysaccharide matrices for microbially triggered drug delivery to the colon. Drug Dev Ind Pharm, 30:143-150. (Pubitemid 38420258)
13. Gazzaniga A, Iamartino P, Maffione G, Sangalli ME. (1994). Oral delayed-release system for colonic specific delivery. Int J Pharm, 108:77-83. (Pubitemid 24207344)
14. Zhang L, Chen DW, Gao ZB. (2006). [Drug release mechanism of famotidine time-Controlled release pellets]. Yao Xue Xue Bao, 41:873-877. (Pubitemid 44671731)
15. Davis SS, Hardy JG, Taylor MJ, Stockwell A, Whalley DR, Wilson CG. (1984). The in-vivo evaluation of an osmotic device (Osmet) using gamma scintigraphy. J Pharm Pharmacol, 36:740-742. (Pubitemid 14021954)
16. Dvorácková K, Rabišková M, Muselík J, Gajdziok J, Bajerová M. (2011). Coated hard capsules as the pH-Dependent drug transport systems to ileo-Colonic compartment. Drug Dev Ind Pharm, 37:1131-1140.
17. Sasaki Y, Hada R, Nakajima H, Fukuda S, Munakata A. (1997). Improved localizing method of radiopill in measurement of entire gastrointestinal pH profiles: Colonic luminal pH in normal subjects and patients with Crohn's disease. Am J Gastroenterol, 92:114-118. (Pubitemid 27027040)
18. Lamprecht A, Kawashima Y. (2006). pH-Sensitive microparticles for oral drug delivery. J Drug Del Sci Tech, 16:26-34.
19. Rhodes CT, Porter SC. (1998). Coatings for controlled-release drug delivery systems. Drug Dev Ind Pharm, 24:1139-1154. (Pubitemid 28546094)
20. Akhgari A, Afrasiabi Garekani H, Sadeghi F, Azimaie M. (2005). Statistical optimization of indomethacin pellets coated with pH-Dependent methacrylic polymers for possible colonic drug delivery. Int J Pharm, 305:22-30. (Pubitemid 41562214)
21. Rubinstein A. (1990). Microbially controlled drug delivery to the colon. Biopharm Drug Dispos, 11:465-475. (Pubitemid 20271436)
22. Kadam VD, Gattani SG. (2010). Development of colon targeted multiparticulate pulsatile drug delivery system for treating nocturnal asthma. Drug Deliv, 17:343-351.
23. Gao C, Huang J, Jiao Y, Shan L, Liu Y, Li Y et al. (2006). In vitro release and in vivo absorption in beagle dogs of meloxicam from Eudragit FS 30 D-Coated pellets. Int J Pharm, 322:104-112. (Pubitemid 44331530)
24. Khan KA. (1975). The concePTof dissolution efficiency. J Pharm Pharmacol, 27:48-49.
25. Philip AK, Pathak K. (2006). Osmotic flow through asymmetric membrane: A means for controlled delivery of drugs with varying solubility. AAPS Pharm Sci Tech, 7:56.
26. Blanco MD, Guerrero S, Benito M, Fernández A, Teijón C, Olmo R, Katime I, Teijón JM. (2011). In vitro and in vivo evaluation of a folate-Targeted copolymeric submicrohydrogel based on n-Isopropylacrylamide as 5-Fluorouracil delivery system. Polymers, 3:1107-1125.
27. Erkoboni DF. (2003). Extrusion/Spheronization. In: Ghebre-Sellassie I, Martin C, (ed.) Pharmaceutical Extrusion Technology. New York: Marcel Dekker Inc, pp. 249-280.
28. Mezreb N, Charrueau C, Boy P, Allain P, Chaumeil JC. (2004). Production of Carbopol 974P and Carbopol 971P pellets by extrusion-Spheronization: Optimization of the processing parameters and water content. Drug Dev Ind Pharm, 30:481-490. (Pubitemid 38821859)
29. Vervaet C, Baert L, Remon JP. (1995). Extrusion-Spheronisation A literature review. Int J Pharm, 116:131-146.
30. Häring A, Vetchý D, Janovská L, Krejcová K, Rabisková M. (2008). Differences in characteristics of pellets prepared by different pelletization methods. Drug Dev Ind Pharm, 34:289-296. (Pubitemid 351431195)
31. Hileman GA, Goskonda SR, Spalitto AJ, Upadrashta SM. (1993). Response surface optimization of high dose pellets by extrusion and spheronization. Int J Pharm, 100:71-79. (Pubitemid 23316318)
32. Knop K. (1996). Influence of buffer solution composition on drug release from pellets coated with neutral and quaternary acrylic polymers and on swelling of free polymer films. Eur J Pharm Sci, 4:293-300. (Pubitemid 26346082)
33. Zhao X, Li G, Zhang L, Tao X, Guan T, Hong M et al. (2010). Preparation and evaluation of nicotinic acid sustained-release pellets combined with immediate release simvastatin. Int J Pharm, 400:42-48.
34. Amighi K, Moes AJ. (1997). Influence of curing conditions on the drug release rate from Eudragit® NE30D film coated sustainedrelease theophylline pellets. STP Pharma Sci, 7:141-147.
35. Sriamornsak P, Nunthanid J, Luangtana-Anan M, Puttipipatkhachorn S. (2007). Alginate-based pellets prepared by extrusion/spheronization: A preliminary study on the effect of additive in granulating liquid. Eur J Pharm Biopharm, 67:227-235. (Pubitemid 46991312)